To pursue -- by itself and with partners -- the work that earlier this year bagged the company an expansion of its deal with Taisho Pharmaceutical Ltd. focused on G protein-coupled receptors, Arena Pharmaceuticals Inc. priced its Follow-on offering of 5 million shares at $27.50 per share. The sale of 4 million shares by the San Diego-based firm raised $110 million, and the remainder was sold by stockholders. Arena, with 160 employees, went public last July, raising $108 million by selling 6 million shares at $18 each. After the most recent offering, the company has 26.7 million shares outstanding. It registered for the follow-on earlier in June.
No comments:
Post a Comment